Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ERGO
Entia Biosciences
$0.00
$0.00
$0.00
▼
$0.04
N/A29.71279 shsN/A
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
$1.37
-3.9%
$1.91
$1.14
▼
$4.26
$34.67M1.291.33 million shs28,435 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ERGO
Entia Biosciences
0.00%+130.00%+1,050.00%+1,050.00%+2,200.00%
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
+2.16%-0.70%-17.44%-45.80%+141,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ERGO
Entia Biosciences
$0.00
$0.00
$0.00
▼
$0.04
N/A29.71279 shsN/A
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
$1.37
-3.9%
$1.91
$1.14
▼
$4.26
$34.67M1.291.33 million shs28,435 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ERGO
Entia Biosciences
0.00%+130.00%+1,050.00%+1,050.00%+2,200.00%
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
+2.16%-0.70%-17.44%-45.80%+141,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ERGO
Entia Biosciences
0.00
N/AN/AN/A
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
3.00
Buy$8.00479.71% Upside

Current Analyst Ratings Breakdown

Latest AMYT, VEC, SER, and ERGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
Reiterated RatingBuy
10/26/2026
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
Reiterated RatingBuy$8.00
9/10/2026
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
Reiterated RatingBuy$8.00
(Data available from 11/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ERGO
Entia Biosciences
N/AN/AN/AN/AN/AN/A
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
$130K269.63N/AN/A($0.46) per share-3.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ERGO
Entia Biosciences
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
-$19.18MN/AN/AN/AN/AN/A-416.40%-132.69%N/A

Latest AMYT, VEC, SER, and ERGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
N/A-$0.31N/A-$0.31N/A$0.13 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ERGO
Entia Biosciences
N/AN/AN/AN/AN/A
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ERGO
Entia Biosciences
N/AN/AN/A
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
0.16
6.65
6.65

Institutional Ownership

CompanyInstitutional Ownership
ERGO
Entia Biosciences
N/A
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
12.50%

Insider Ownership

CompanyInsider Ownership
ERGO
Entia Biosciences
28.30%
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
17.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
ERGO
Entia Biosciences
6N/AN/ANot Optionable
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
1625.40 million20.90 millionN/A

Recent News About These Companies

Serina Therapeutics (NYSEAMERICAN:SER) Stock Price Up 2.2% - Still a Buy?

Entia Biosciences OTCMKTS:ERGO

$0.0023 0.00 (0.00%)
As of 11/13/2026

Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.

Serina Therapeutics stock logo

Serina Therapeutics NYSEAMERICAN:SER

$1.36 -0.06 (-3.87%)
Closing price 04:10 PM Eastern
Extended Trading
$1.36 0.00 (-0.07%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.